Powered by
RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S.
Sep 14, 2017 - News Bites Canadian Markets
Board and Executive Moves

CANADIAN DAILY STOCK REPORT

Corporate Wire Date: 13 September 2017 19:45 EDT

ORIGINAL ANNOUNCEMENT [Text]

Esomeprazole Strontium Delayed-Release (DR) Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI) indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions

PPIs are one of the most commonly prescribed classes of medications in the U.S., with an estimated market value

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 10 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox